Raptor Pharmaceuticals News

Raptor Pharmaceutical Corp. , announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of parasitic diseases, including malaria, from McGill University in Montreal, Canada.

NOVATO, Calif., May 3, 2012 -- Raptor Pharmaceutical Corp. , announced the online publication of an article titled, "A Randomized Controlled Crossover Trial with a Delayed Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on WBC Cystine Levels and Comparison of Safety" in the Clinical Journal of the American Society of ... (more)

Some quick facts as to why Raptor Pharmaceuticals could be on the verge of attracting increased attention from biotech investors given the upcoming catalysts, strong pipeline, cash position and impressive leadership team.

Raptor Pharmaceutical Corp. Press release Raptor Pharmaceutical Announces At-the-Market Common Stock Sales Program NOVATO, Calif., 2012-05-01 12:00 CEST -- Raptor Pharmaceutical Corp.